A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...
Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...
TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results